Einav Nili Gal-Yam
Advertisement
Articles by Einav Nili Gal-Yam
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD
2
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
3
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
4
Ziftomenib Combo Exhibits Tolerability/Early Activity in NPM1/KMT2A+ AML
5
